What is Wedbush’s Estimate for ANRO FY2029 Earnings?

Alto Neuroscience, Inc. (NYSE:ANRO) – Investment analysts at Wedbush issued their FY2029 EPS estimates for shares of Alto Neuroscience in a note issued to investors on Thursday, March 20th. Wedbush analyst L. Chico anticipates that the company will earn ($2.88) per share for the year. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.54) per share.

Separately, William Blair reaffirmed an “outperform” rating on shares of Alto Neuroscience in a report on Friday. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $16.75.

Alto Neuroscience Trading Down 0.2 %

ANRO stock opened at $2.65 on Monday. Alto Neuroscience has a 52 week low of $2.58 and a 52 week high of $18.35. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.09 and a current ratio of 13.10. The company’s 50-day simple moving average is $3.60 and its 200 day simple moving average is $5.98. The company has a market capitalization of $71.34 million and a PE ratio of -1.04.

Alto Neuroscience (NYSE:ANRO) last announced its earnings results on Thursday, March 20th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.09.

Institutional Trading of Alto Neuroscience

Several institutional investors and hedge funds have recently modified their holdings of the business. Wells Fargo & Company MN grew its holdings in shares of Alto Neuroscience by 40.0% during the 4th quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock valued at $46,000 after purchasing an additional 3,139 shares during the last quarter. Deutsche Bank AG increased its stake in shares of Alto Neuroscience by 31.3% in the fourth quarter. Deutsche Bank AG now owns 15,210 shares of the company’s stock valued at $64,000 after buying an additional 3,629 shares during the period. BNP Paribas Financial Markets grew its holdings in Alto Neuroscience by 619.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock worth $49,000 after acquiring an additional 3,715 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Alto Neuroscience by 24.4% in the fourth quarter. Rhumbline Advisers now owns 25,556 shares of the company’s stock worth $108,000 after purchasing an additional 5,008 shares during the last quarter. Finally, Philadelphia Financial Management of San Francisco LLC raised its position in Alto Neuroscience by 1.5% during the 3rd quarter. Philadelphia Financial Management of San Francisco LLC now owns 449,952 shares of the company’s stock worth $5,147,000 after purchasing an additional 6,663 shares during the last quarter.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.